Krisztina Herszényi
Semmelweis University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Krisztina Herszényi.
Journal of The European Academy of Dermatology and Venereology | 2015
Fanni Rencz; Péter Holló; Sarolta Kárpáti; Márta Péntek; Éva Remenyik; Andrea Szegedi; Orsolya Balogh; Emese Herédi; Krisztina Herszényi; Hajnalka Jókai; Valentin Brodszky; László Gulácsi
Unrealistic expectations regarding treatments and clinical outcomes may lead to disappointment about therapy and sub‐optimal compliance; nonetheless, these expectations have not been studied in psoriasis patients yet.
Orvosi Hetilap | 2014
Fanni Rencz; Valentin Brodszky; Márta Péntek; Orsolya Balogh; Éva Remenyik; Andrea Szegedi; Péter Holló; Sarolta Kárpáti; Hajnalka Jókai; Krisztina Herszényi; Emese Herédi; Sándor Szántó; László Gulácsi
INTRODUCTION Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. AIM To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. METHOD A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. RESULTS Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively. CONCLUSIONS Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.
Journal of The European Academy of Dermatology and Venereology | 2018
Fanni Rencz; Adrienn Katalin Poór; Márta Péntek; Péter Holló; Sarolta Kárpáti; László Gulácsi; Andrea Szegedi; Éva Remenyik; Bernadett Hidvégi; Krisztina Herszényi; Hajnalka Jókai; Zsuzsanna Beretzky; Valentin Brodszky
Dermatology Life Quality Index (DLQI) is the most common health‐related quality of life measure in dermatology that is widely used in treatment guidelines for psoriasis. Eight of the 10 questions of the DLQI offer a ‘not relevant’ response (NRR) option that is scored as the item had no impact on patients’ life at all.
Orvosi Hetilap | 2015
Péter Holló; Hajnalka Jókai; Krisztina Herszényi; Sarolta Kárpáti
Sexually transmitted infections of the urogenital tract are most commonly caused by the intracellular bacteria Chlamydia trachomatis worldwide, resulting the clinical picture of acute urethritis in men as well as urethritis and endocervicitis in women. As women often present with few symptoms only or a completely symptom-free disease course, one of the most important long-term complications is chronic pelvic inflammatory disease often followed by the development of infertility caused by chronic scar formation. Well-organized screening programs are considered to have a leading role in the prevention of disease spreading and long lasting unwanted complications. Antibiotic treatment options are often influenced by special circumstances, such as pregnancy and several complicated clinical forms. The aims of the authors are to give a concise review on the current knowledge regarding Chlamydia trachomatis infections and summarize typical clinical signs, modern diagnostic techniques as well as accepted treatment protocols and basic aspects of screening.
Orvosi Hetilap | 2015
Péter Holló; Hajnalka Jókai; Krisztina Herszényi; Sarolta Kárpáti
Sexually transmitted infections of the urogenital tract are most commonly caused by the intracellular bacteria Chlamydia trachomatis worldwide, resulting the clinical picture of acute urethritis in men as well as urethritis and endocervicitis in women. As women often present with few symptoms only or a completely symptom-free disease course, one of the most important long-term complications is chronic pelvic inflammatory disease often followed by the development of infertility caused by chronic scar formation. Well-organized screening programs are considered to have a leading role in the prevention of disease spreading and long lasting unwanted complications. Antibiotic treatment options are often influenced by special circumstances, such as pregnancy and several complicated clinical forms. The aims of the authors are to give a concise review on the current knowledge regarding Chlamydia trachomatis infections and summarize typical clinical signs, modern diagnostic techniques as well as accepted treatment protocols and basic aspects of screening.
Orvosi Hetilap | 2014
Péter Holló; Hajnalka Jókai; Krisztina Herszényi; Sarolta Kárpáti
Sexually transmitted infections of the urogenital tract are most commonly caused by the intracellular bacteria Chlamydia trachomatis worldwide, resulting the clinical picture of acute urethritis in men as well as urethritis and endocervicitis in women. As women often present with few symptoms only or a completely symptom-free disease course, one of the most important long-term complications is chronic pelvic inflammatory disease often followed by the development of infertility caused by chronic scar formation. Well-organized screening programs are considered to have a leading role in the prevention of disease spreading and long lasting unwanted complications. Antibiotic treatment options are often influenced by special circumstances, such as pregnancy and several complicated clinical forms. The aims of the authors are to give a concise review on the current knowledge regarding Chlamydia trachomatis infections and summarize typical clinical signs, modern diagnostic techniques as well as accepted treatment protocols and basic aspects of screening.
Orvosi Hetilap | 2014
Fanni Rencz; Valentin Brodszky; Márta Péntek; Orsolya Balogh; Éva Remenyik; Andrea Szegedi; Péter Holló; Sarolta Kárpáti; Hajnalka Jókai; Krisztina Herszényi; Emese Herédi; Sándor Szántó; László Gulácsi
INTRODUCTION Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. AIM To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. METHOD A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. RESULTS Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively. CONCLUSIONS Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.
European Journal of Health Economics | 2014
Emese Herédi; Fanni Rencz; Orsolya Balogh; László Gulácsi; Krisztina Herszényi; Péter Holló; Hajnalka Jókai; Sarolta Kárpáti; Márta Péntek; Éva Remenyik; Andrea Szegedi; Valentin Brodszky
The Journal of Allergy and Clinical Immunology | 2016
Ester Ruiz-Romeu; Marta Ferran; Marc Sagristà; Julià Gómez; Ana Giménez-Arnau; Krisztina Herszényi; Péter Holló; Antonio Celada; Ramon M. Pujol; Luis F. Santamaria-Babí
European Journal of Health Economics | 2014
Orsolya Balogh; Valentin Brodszky; László Gulácsi; Emese Herédi; Krisztina Herszényi; Hajnalka Jókai; Sarolta Kárpáti; Petra Baji; Éva Remenyik; Andrea Szegedi; Péter Holló